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Summary
Phellinus baumii is a mushroom used as a folk medicine for a variety of human dis-
eases in several Asian countries. Recently we have reported for the first time about the
antidiabetic effect of the crude exopolysaccharides (EPS) produced from submerged my-
celial culture of P. baumii in streptozotocin (STZ)-induced diabetic rats. The diabetic rats
study revealed that orally administrated P. baumii EPS lowered the blood glucose levels
and stimulated insulin excretion in diabetic rats, and consequently restored the functions
of pancreas, liver, and kidney, suggesting that the EPS might be useful for the manage-
ment of human diabetes mellitus. We undertook proteomic analyses for plasma, pancreas,
liver, and kidney of the rats to search for novel biomarkers for monitoring diabetes before
and after EPS treatments. In this article, we describe the production of EPS in submerged
culture of P. baumii and studies of their hypoglycemic activity. We also explore the issue of
proteomic analyses for mining biomarkers of diabetes.
Key words: diabetes mellitus, exopolysaccharides, hypoglycemic effect, Phellinus baumii,
proteome
Introduction
Microbial exopolysaccharides (EPS) are a class of high
value biopolymers with a wide variety of industrial ap-
plications (1,2). In particular, many kinds of EPS have
been produced from submerged cultures of basidiomyce-
tes or entomopathogenic fungi (3–22) because solid cul-
ture does not guarantee a standardized product, with pro-
duct composition varying from batch to batch (23–27).
Phellinus spp., basidiomycetes belonging to the fam-
ily Polyporaceae, have diverse physiological effects, espe-
cially antitumor activity (25,28–31). The fruiting bodies
of P. baumii and P. linteus are used as a folk medicine for
a variety of human diseases in several Asian countries.
Pharmacological activities ascribed to polysaccharide-
-containing extracts of these fruiting bodies include anti-
oxidant activity and prevention of acute pulmonary in-
flammation (32,33). However, although there are a great
number of reports about the pharmacological activities
of EPS from fruiting bodies of Phellinus species (34,35),
there are few published reports about the production of
EPS in submerged culture and characterization of their
biological activities (8,10,12). Recently, we have found
that EPS produced in submerged cultures of P. baumii
showed strong antidiabetic activity against streptozoto-
cin (STZ)-induced diabetic rats (16).
Though different types of oral hypoglycemic agents
are available, along with insulin, for the treatment of di-
abetes mellitus, there is increasing demand by patients
to use natural products. Insulin cannot be used orally
and continuous use of the synthetic antidiabetic drugs
causes side effects and toxicity (36,37). Due to their ef-
fectiveness, limited side effects, and relatively low cost,
herbal drugs are widely prescribed even when their bio-
logically active compounds are unknown. In many coun-
tries, much effort has been put into the discovery of na-
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tural antidiabetic drugs from various medicinal plants
(38–54). Mushrooms and entomopathogenic fungi are also
potential sources of natural medicines with antidiabetic
activity. Many investigators have tested the fruiting bod-
ies or mycelia of various edible/medicinal fungi for
hypoglycemic effects (41,55–62), but little attention has
been given to EPS obtained by mycelial culture (63–68).
There are numerous marker proteins for the diagno-
sis of diabetes mellitus (69–73), but there has been no
proteomic study of diabetes before and after the treat-
ment with natural antidiabetic remedies, such as mush-
rooms and other herbal medicines. It is interesting to
link proteomics technology to the discovery of diabe-
tes-associated proteins (biomarkers), which is possible
by detailed analysis of those proteins after treatment
with fungal polysaccharides (see Fig. 1). In this paper,
we describe the production of EPS of P. baumii by sub-
merged culture and characterization of their hypoglyce-
mic activity. We also explore possible applications to pro-
teomic analyses for mining biomarkers of diabetes.
Materials and Methods
Microorganism and culture procedure
Phellinus baumii DG-07 was used throughout the ex-
periments. The stock culture was inoculated on a potato
dextrose agar (PDA) slant, incubated at 28 °C for 6 days
and then stored at 4 °C. It was subcultured monthly. For
inoculum preparation, P. baumii was grown on a PDA
medium (2.4 % potato dextrose broth and 2 % agar) in a
Petri dish, and then transferred to the seed culture me-
dium by punching out a portion (5 mm diameter) of the
agar plate with a sterilized homemade cutter. The seed
culture was grown in a 250-mL flask containing 50 mL
of PMP medium (2.4 % potato dextrose broth, 1 % malt
extract, 0.1 % peptone) at 28 °C with shaking at 150 rpm
for 4 days. Submerged culture of P. baumii for the pro-
duction of EPS was performed in a 5-litre stirred-tank
fermentor under the following culture conditions: fruc-
tose 20 g/L, yeast extract 20 g/L, CaCl2 0.55 g/L, tem-
perature 30 °C, aeration rate 2 vvm, agitation speed 150
rpm, initial pH=5.0, and working volume 3 L.
Measurements of rheology and morphology
Morphological details of the samples were evaluated
using an image analyzer with software coupled to a light
microscope through a charge-coupled device (CCD) ca-
mera according to the method outlined by Tucker and
Thomas (74). Rheological measurements were performed
on samples collected from the bioreactor at regular in-
tervals using a digital viscometer (Brookfield Engineer-
ing Laboratories, Inc., Stoughton, MA, USA) fitted with
a small sample adapter. Culture broths were centrifuged
at 10 000×g for 20 min, and the supernatant was filtered
through a Whatman filter paper No. 2 (Whatman Inter-
national Ltd., Maidstone, UK). The resulting culture fil-
trate was mixed with four volumes of absolute ethanol,
stirred vigorously and left overnight at 4 °C. The precip-
itated EPS was centrifuged at 10 000×g for 20 min and
the supernatant was discarded. The precipitates of crude
EPS were lyophilized and the mass was estimated. Dry
mass of the mycelium was measured after repeated wash-
ing of the mycelial pellet with distilled water and dry-
ing at 90 °C overnight to constant mass.
Purification of the EPS
The ethanol precipitates of the crude EPS components
were dissolved in 0.2 M NaCl buffer to the concentra-
tion of 10 g/L, and loaded onto a Sepharose CL–4B col-
umn (2.4 cm×100 cm, Sigma Chemical Co., Louis, MO,
USA). The column was eluted with the same buffer at a
flow rate of 0.6 mL/min. The total carbohydrate content
of the EPS produced from P. baumii was determined by
the phenol sulfuric acid method (75) using glucose as
the standard. Total protein was determined by the me-
thod of Lowry et al. (76) with bovine serum albumin as
the standard. The protein moiety in the EPS was moni-
tored by absorbance at 280 nm, whilst the carbohydrate
moiety was monitored at 480 nm.
Diabetic rats study
Male Sprague-Dawley rats (Daehan Experimental An-
imals, Seoul, Korea), weighing 130–150 g, were housed
in individual stainless steel cages and acclimatized with
free access to food and water for at least one week in an
air conditioned room ((23±2) °C with (55±5) % humid-
ity) under a 12:12-hour light-dark cycle. The rats were
fed with a commercial pellet diet (Sam Yang Co., Seoul,
Korea) throughout the experimental period.
After one week of acclimatization, the rats were
subjected to a 16-hour fast. Diabetes was induced by in-













Fig. 1. A strategy for the application of fungal polysaccharides
to diabetic proteomics
tramuscular injection of streptozotocin (STZ; Sigma Che-
mical Co., Louis, MO, USA) dissolved in 0.01 M sodium
citrate buffer (pH=4.5) at a dose of 50 mg/kg body mass
(77). Two days after the injection of the STZ, fasting
blood glucose was determined and the rats with blood
glucose >300 mg/dL were included in the group of dia-
betics. All the animals were randomly divided into four
groups with six animals in each group: Group N: nor-
mal control rat group was treated with 0.9 % NaCl solu-
tion; Group NP: normal control rat group was treated
with Phellinus baumii EPS at the level of 200 mg/kg bo-
dy mass; Group S: STZ-induced diabetic rat group, the
so-called diabetic control rats, which were treated with
0.9 % NaCl solution; Group SP: STZ-induced diabetic
rats treated with Phellinus baumii EPS at the level of 200
mg/kg body mass daily for 14 days.
Blood samples for the proteomics study were ob-
tained without anesthesia by resection of the terminal
1–2 mm of the rats’ tails after 14 days; a total of 0.5–0.6
mL of blood was drawn into tubes containing sodium
EDTA. Plasma was separated by centrifugation (3000g,
10 min) and then stored at –30 °C until analysis. The
protein content of plasma samples was determined us-
ing the Bradford method (78) with protein assay dye re-
agent concentrate (Bio-Rad, Hercules, CA, USA).
Two-dimensional electrophoresis for the
proteomic study
Rat tissues (e.g. liver, kidney, and pancreas) were re-
moved immediately after sacrifice. Excess blood was
eliminated from the tissues using a cold NaCl solution.
Each tissue was pulverized into a powder under liquid
nitrogen and stored at –80 °C until use. Frozen tissues
(40 mg) were solubilized in 200 mL of rehydration buffer
containing 7 M urea, 2 M thiourea, 4 % 3-((3-cholamidopro-
pyl)dimethylammonio)-1-propanesulfonic acid (CHAPS),
1 mM phenylmethylsulfonylfluoride (PMSF), 20 mM di-
thiothreitol (DTT), 2 % immobilized pH gradient (IPG)
buffer and a trace of bromophenol blue. An ultrasonic
generator was used for 2×30 s with 1 min on ice be-
tween each round to aid solubilization. Samples were cen-
trifuged at 13 000×g for 15 min and then the supernatant
was transferred into new tubes. Protein from the
supernatant was precipitated by methanol/chloroform
prior to electrophoretic separation. The precipitate was
resuspended in rehydration buffer and then kept at –80
°C until use.
Two-dimensional electrophoresis images were made
in triplicate for the three rats in normal (Group N), dia-
betic control (Group S), and EPS-treated diabetic (Group
SP) groups (i.e. a total of 9 gel images for each group)
and normalized prior to statistical analysis. IPG isoelec-
tric focusing (IEF) of samples was carried out on pH=4–7
or pH=3–10, 17 cm IPG DryStrips (Bio-Rad) in the Pro-
tean IEF cell (Bio-Rad) using the protocol recommended
by the manufacturer. IPG strips were rehydrated passive-
ly overnight in strip holders in 350 mL of rehydration
solution containing 3 mL of plasma sample. IEF was car-
ried out as follows: 15 min at 250 V, 3 h at 250–10 000 V,
6 h at 10 000 V, and then held at 500 V until ready to
run the second dimension. Briefly, 200 mg (3 mL) of the
plasma sample were mixed with 347 mL of rehydration
solution containing 7 M urea, 2 M thiourea, 4 % CHAPS,
1 mM PMSF, 20 mM DTT and 2 % IPG buffer. After fo-
cusing, the gel strips were equilibrated in a solution
containing 6 M urea, 2 % SDS, 1 % DTT, 30 % glycerol,
and 50 mM Tris-HCl (pH=6.8) for 15 min, followed by
further incubation in the same solution (except that DTT
was replaced with 2.5 % iodoacetamide) for additional
15 min. The equilibrated IPG strips were gently rinsed
with electrophoretic buffer and then placed on a 2020
cm 12 % polyacrylamide gel for resolution in the second
dimension. The fractionation was performed with the
Laemmli-SDS-discontinuous system, at a constant volt-
age of 20 mA per gel for 10 h, after which the gels were
visualized by silver staining.
Gels were imaged on a UMAX PowerLook 1120
(Maxium Technologies, Inc., Taipei, Taiwan) and the re-
sulting 16-bit images were converted to TIF format prior
to exporting and analysis. Intensity calibration was car-
ried out using an intensity stepwedge before gel image
capture. Images were compared using a modified ver-
sion of ImageMaster 2D software ver. 4.95 (Amersham
Biosciences, Little Chalfont, Buckinghamshire, UK). A
reference gel was selected at random from the gels of
the control group for each experiment and detected spots
from the other gels in the control data set were matched
to those in the selected reference gel. The relative absor-
bance and relative volume were also calculated in order
to correct for differences in gel staining. Each spot inten-
sity volume was processed by background subtraction
and total spot volume normalization; the resulting spot
volume percentage was used for comparison.
Protein identification
Enzymatic in-gel digestion of protein spots was sim-
ilar to that described by Shevchenko et al. (79), using
modified porcine trypsin. Gel pieces were washed with
50 % acetonitrile to remove SDS, salts, and stains. The
gel was then dried to remove solvent, rehydrated with
trypsin (8–10 ng/mL), and incubated for 8–10 h at 37 °C.
The proteolytic reaction was terminated by adding 5 mL
of 0.5 % trifluoroacetic acid. Tryptic peptides were re-
covered by combining the aqueous phase from several
extractions of gel pieces with 50 % acetonitrile. After
concentration, the peptide mixture was redissolved in
the buffer and desalted using C18ZipTips (Millipore),
and the peptides were eluted with 1–5 mL of acetonitrile.
An aliquot of this solution was mixed with an equal vol-
ume of a saturated solution of a-cyano-4-hydroxycinna-
mic acid in 50 % acetonitrile, and 1 mL of the mixture
spotted onto a target plate.
Protein analysis was done using an Ettan MALDI-
-ToF mass spectrometer (Amersham Biosciences). The
peptides were evaporated with an N2 laser at 337 nm
using a delayed extraction mode. They were accelerated
with a 20 kV injection pulse for a time of flight analysis.
Each spectrum was the cumulative average of 300 laser
shots. The search program ProFound, developed by the
Rockefeller University (80), was used for protein identi-
fication by peptide mass fingerprinting. Spectra were ca-
librated with trypsin auto-digestion ion peak m/z (842.510,
2211.1046) as internal standards.
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Statistical analysis
All experimental results were compared by one-way
analysis of variance (ANOVA) using the Statistical Pack-
age of Social Science (SPSS) program and the data were
expressed as means ± standard error (S.E.). Group mean
values were considered to be significantly different at
p<0.05, as determined by the technique of protective
least-significant difference (LSD) when ANOVA indi-
cated an overall significant treatment effect, p<0.05.
Results and Discussion
Submerged culture of P. baumii
P. baumii grows well under the following conditions:
fructose 20 g/L, yeast extract 20 g/L, CaCl2 0.55 g/L,
pH=5.0, and 30 °C (12). Under these conditions, the ma-
ximum mycelial biomass and EPS obtained in a 5-liter
stirred-tank bioreactor were 17.6 and 3.8 g/L, respective-
ly (Fig. 2A).
During fermentation, the morphology of P. baumii
changed from small pellets with radial growth of fila-
mentous mycelia to small feather-like mycelial clumps.
Pellets fragmented rapidly after day 12 due to prolonged
agitation, depletion of substrate, changing pH, and oxy-
gen limitation inside the pellet. Subsequently, the mean
equivalent diameter dropped from 5.2 mm to 2.6 mm
(Fig. 2B). The pellet circularity of P. baumii remained un-
changed throughout the entire culture period.
The broth rheology in fungal fermentations depends
on the morphology and on the yields of mycelial bio-
mass and EPS. The apparent viscosity of the fermenta-
tion broth increased rapidly during the early culture pe-
riod, and then a rapid drop was observed at a later stage
of the culture period (Fig. 2C). This drop in viscosity was
related to the fragmentation into small feather-like my-
celial clumps. The apparent viscosity was influenced more
by the mycelial biomass concentration than by the EPS
concentration. The culture broth of P. baumii had ex-
tremely high apparent viscosities. Fig. 2D shows the
variations in the consistency index (K) and the flow be-
havior index (n) of the fermentation broth. The consis-
tency index (K) rose from the beginning of the fermenta-
tion for 14 days and then declined. This behavior is quite
common for liquid fermentations of mushrooms (81,82).
The morphology of fungi during submerged culture
is related to their metabolic activities (81,83,84). Many
investigators claim that the different morphology of fun-
gal mycelia under different initial pH values is one of
the most important factors affecting biomass accumula-
tion and metabolite formation (85,86). The mycelial mor-
phology of P. baumii was very sensitive to the culture
pH and culture time (Fig. 3).
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Fig. 2. (A) Typical time profiles of mycelial biomass and exopolysaccharide concentration, (B) mycelial pellet sizes, (C) apparent vis-
cosity, and (D) consistency index and flow behavior index in submerged mycelial culture of Phellinus baumii
Chemical compositions of the EPS
The crude EPS was purified by gel filtration in a Se-
pharose CL–4B column. Two different heteropolysaccha-
rides and two proteoglycans were eluted. The carbohy-
drate and protein contents in the crude EPS were 71.0
and 29.0 %, respectively. The protein moiety of the crude
EPS consisted mainly of arginine (14.1 %) and glycine
(12.0 %), while the carbohydrate moiety consisted main-
ly of mannose (48.7 %) and arabinose (38.4 %).
Hypoglycemic effect of the EPS
The food intake of the diabetic control rats (Group
S) increased by 28.1 %, whereas body mass gain was re-
duced by about 44.1 % as compared to the normal con-
trol rats (Group N). Moreover, STZ-treated rats (Groups
S and SP) also had a markedly lower food efficiency ra-
tio than those in the N and NP groups (16). Fig. 4 shows
the plasma glucose level in the various rat groups over a
14-day period. In the two diabetic groups (S and SP),
the initial concentrations of plasma glucose were almost
the same, with both groups within the error range. In
the diabetic control group (Group S), the plasma glucose
level continuously increased during the experimental
period, reaching a final level of 610 mg/L. In contrast,
the administration of P. baumii EPS lowered the plasma
glucose level of the Group SP rats by 52 % on day 14,
when compared to that of the diabetic control group
(Group S). Also, a remarkable reduction of aspartate
aminotransferse (AST) and alanine aminotransferse (ALT)
levels upon oral administration of P. baumii EPS indi-
cates a remedial effect on the liver function. There were
no significant differences in the mass of the heart and
pancreas, whereas those of the liver, spleen, kidney, and
lung were considerably increased in the diabetic groups
(Groups S and SP), as compared to Group N (16).
The hypoglycemic activity of P. baumii EPS pro-
duced in submerged culture is better than that of poly-
saccharides from fruiting bodies or mycelial extracts.
Furthermore, the EPS from submerged culture is more
practical for use in medical practice because a compli-
cated extraction process is required in order to obtain
polysaccharides from the fruiting body and it is difficult
to obtain a uniform chemical composition.
The chemical structure and viscosity of mushroom
polysaccharides are related to the hypoglycemic activity
(55,56,59,87,88). Administration of EPS from P. baumii
counteracted the diabetogenic effect of STZ, which in-
volves the induction of the generation of reactive oxy-
gen species (ROS) in rat islets. EPS treatment reduces
the degree of diabetes by reducing STZ-induced destruc-
tion of b-cells. The oral administration of P. baumii EPS
therefore has potential in preventing diabetes, since pan-
creatic damage induced by environmental chemicals and
other factors is a cause of diabetes (61).
Effect of EPS on the plasma proteome of diabetic rats
We obtained good resolution of plasma proteins by
using a system in which the first dimension separation
was carried out in a pH=4–7 IEF strip. The plasma maps
obtained from our gels showed a pattern similar to
those of The Rat Serum Protein Study Group (89). As
shown in Fig. 5, less than 500 individual spots were de-
tected, with masses ranging from 6 to 200 kDa and
isoelectric points ranging between pH=4–7. Nineteen
proteins from these spots were found to be differentially
regulated, of which 17 spots were identified as principal
diabetes-associated proteins.
The distinct effect of diabetes induction on the pat-
tern of rat plasma proteins includes the downregulation
of albumin, Apo E, a1-inhibitor-3, fetuin b, Gc-globulin,
hemopexin, vitronectin, and transthyretin monomer, and
the upregulation of Apo A-I, Apo A-IV, ceruloplasmin,
a1-antitrypsin, serine protease inhibitor III, and transfer-
rin. Interestingly, levels of these proteins were restored
to those of healthy rats by EPS treatment, although the
order of magnitude of the changes differed widely. Two
proteins showed distinct differential expression with op-
posite trends: transthyretin tetramer was significantly
downregulated and Ig kappa light chain was signifi-
cantly upregulated upon diabetes induction; both of
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Fig. 3. Morphological changes in mycelia of Phellinus baumii in
different culture pH (upper panels) and culture time (lower pa-
nels) in a stirred-tank bioreactor
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Fig. 4. Plasma glucose levels in the various rat groups during
two weeks. Group N (), Group NP (), Group S (), Group
SP (). EPS and buffer were administrated 48 h after diabetes
induction. All data are expressed as mean ± S.E. (p<0.05). Data
points for Group N and Group NP are incorporated together
because they showed no significant difference
these proteins were also normalized to levels typical of
those of healthy groups after EPS treatment.
The oxidative stress proteins (Cp and Tf) and pro-
teins related to lipid metabolism (Apo A-I, Apo A-IV,
Apo E) were expressed differently in the STZ–induced
diabetic rats (Fig. 6). Many investigators suggest that di-
abetes is connected with marked alterations in the levels
and distributions of the major apolipoproteins associ-
ated with circulating lipoproteins (90–93).
So far, rat plasma has not been commonly used in
pharmacological and toxicological research. Our study
on rat plasma may stimulate a search for important bio-
markers. The model established in our experiment may
reflect human insulin-requiring diabetes, which will help
us develop biomarkers for human diabetes (94). How-
ever, it is possible that biomarkers that are discovered
using STZ-induced diabetes may be specific for this con-
dition without relevance to natural type 1 diabetes mel-
litus (T1DM) or other types of human diabetes. Further
studies are needed before any conclusions can be made
as to which proteins are important for monitoring the
progression of diabetes or the relevance of our results to
human diabetes.
Our proteomic analysis of rat plasma has enabled
us to be the first to report that a fungal polysaccharide
contributes to normalization of the levels of transthyre-
tin tetramer, Ig kappa light chain, apo A-I, apo E, hapto-
globin, and Gc-globulin, even though the molecular mecha-
nisms for such changes are not clarified yet.
Effect of EPS on the liver proteome of diabetic rats
The liver is one of the central metabolic organs in
the body, playing a key role in regulating and maintain-
ing homeostasis. It is therefore not surprising that many
investigators have found disease-associated target pro-
































14. Ig kappa light chain
2. a2-HS
Fig. 5. Silver-stained rat plasma two-dimensional electrophoresis image. Twenty differentially regulated proteins were marked with
arrows together with identified major rat plasma proteins. Abbreviations: a1-I III: a1-inhibitor III; a1-AT: a1-antitrypsin; a1-M:
a1-macroglobulin; Ab: albumin; Apo: apolipoprotein; Ce: carboxylesterase; Cp: ceruloplasmin; Ct: clusterin; Fn: fibronectin; Ft b:
fetuin beta; Gc: Gc-globulin; Hp: haptoglobin; Hpx: hemopexin; Ht: histamine; Ig: immunoglobulin; KBP: kallikrein-binding protein;
RBP: retinol-binding protein; SPI: serine protease inhibitor; Tf: transferrin; TTR: transthyretin; TTRP: transthyretin precursor; Vn:
vitronectin
teins in liver tissues (95–97). Diabetes is closely linked to
liver dysfunction, as well as to impairment of the pan-
creas. It is also associated with various structural and
functional liver abnormalities, including changes in gly-
cogen metabolism (98), lipid metabolism (99) and anti-
oxidant status (100,101).
In the present proteomic study of diabetes with rat
liver, we identified 69 significantly changed proteins (34
upregulated and 35 downregulated). Of those, 12 were
unidentified proteins that have not been reported to be
related with diabetes mellitus. These numerous diabe-
tes-related changes in protein expression could be asso-
ciated with the appearance of diabetes-related patholo-
gies. Interestingly, all 69 altered proteins in the diabetic
rats were partially or fully restored to levels of those for
non-diabetic control rats upon EPS treatment (for de-
tails, see Fig. 7). Many of the alterations of protein levels
in this study are in accordance with observations noted
previously by other investigators, while 16 proteins were
associated with diabetes mellitus for the first time.
The relationship between the antidiabetic effect of
EPS and the changes in liver protein profiles are still not
clear. Therefore, the molecular basis of protein modula-
tion by EPS in diabetic rats should be explored further.
The results of the proteomic analysis provide impetus
for further molecular and mechanistic studies on the
therapeutic action of EPS, and must be explored before
EPS can be administered as a possible insulin replace-
ment in the management of diabetes mellitus.
Effect of EPS on the kidney proteome of diabetic rats
The kidney eliminates waste products from the pla-
sma and maintains homeostasis of essential cellular bio-
molecules. Since nephrology deals mainly with physiolo-
gy, application of proteomics to renal research is consid-
ered to be a good model to demonstrate that proteomic
data can contribute to physiology and pathophysiology
of many diseases (102–104). Diabetic nephropathy is the
most important cause of death in insulin-dependent dia-
betes mellitus (IDDM), as 30–45 % of the patients even-
tually develop end-stage renal failure (105–107). Al-
though current therapies successfully reduce proteinuria
and slow the rate of progression of diabetic renal injury,
renal failure remains a major complication (108). Thus,
earlier diagnosis and better understanding of the patho-
physiology of diabetic nephropathy are needed to achieve
better therapeutic outcomes. Therefore, extensive efforts
have been made to delineate the pathogenetic mecha-
nisms involved in diabetic nephropathy (109–114).
The two-dimensional electrophoresis image analysis
of kidney proteome showed that 291 spots were differ-
entially expressed among the three experimental groups:

















































































































Fig. 6. Alterations in the levels of the significantly regulated rat
plasma proteins, where down- and upregulated proteins after
diabetes induction are illustrated separately. For each spot, the
relative intensity was averaged and expressed as a mean ± S.E.
of the three separate experiments
*p<0.05 vs. Group N or S, **p<0.001 vs. Group N or S. Nota-























































































Fig. 7. Proteins up- (U) and down- (D) regulated upon STZ
treatment and ameliorated by EPS administration. Each spot in-
tensity volume was processed by background subtraction and
total spot volume normalization; the resulting spot volume per-
centage was used for comparison. All data are expressed as
mean ± S.E. (*p<0.05, **p<0.01, ***p<0.001). Notations for each
group are the same as in Fig. 4. Numbers for protein names:
U4: carbamoyl phosphate synthetase I (CPS I) precursor; U15:
dihydrolipoamide dehydrogenase; U16: methylmalonate semi-
aldehyde dehydrogenase (MMSDH); U28: aldo-keto reductase
family 7, member A2 (aflatoxin aldehyde reductase); U30: chain
D, structure of glycine N-methyltransferase complexed with
S-adenosylmethionine and acetate; U32: cyclin G-associated
kinase (GAK); U33: mitogen-activated protein kinase activator
with WD repeats binding protein (MAWDBP); D1: glucose reg-
ulated protein, 58 kDa; D7: catalase; D11: cytoplasmic b-actin;
D26: mitochondrial H+-ATP synthase á subunit; D27: peroxire-
doxin I (Prx I); D30: nucleoside diphosphate kinase B (NDK B);
D34: chain A, solution structure of cellular retinol binding pro-
tein (RBP) type-I in complex with all-trans-retinol
142 spots were increased and 149 spots were decreased
after induction of diabetes. We excluded those spots that
had a relatively low difference in expression level. This
left 59 spots, which were applied for identification by
MALDI-ToF analysis (data not shown). Consequently, 51
proteins out of 59 spots were identified by peptide mass
fingerprinting (PMF). These proteins showed significant
differences in expression between normal and diabetic
control rats.
Among these 51 proteins, the expression of 26 pro-
teins responded to EPS treatments; the levels of 10 pro-
teins increased after diabetes induction and then de-
creased again to normal values, while the levels of 16
proteins decreased after diabetes induction and then in-
creased again in response to EPS treatment. In particu-
lar, the proteins that were significantly increased after
diabetes induction included E2, phospholipid scram-
blase 3, and 6-pyruvoyl-tetrahydropterin synthase/dime-
rization cofactor of hepatocyte nuclear factor 1 alpha
(Fig. 8). The expression levels of E2 and phospholipid
scramblase 3 increased 3.45-fold and 1.67-fold, respec-
tively, in the STZ-induced diabetic group, and their lev-
els were almost restored to those of normal healthy rats
after EPS treatment (Fig. 8). The expression level of
6-pyruvoyl-tetrahydropterin synthase/dimerization co-
factor of hepatocyte nuclear factor 1 alpha was increased
1.75-fold after diabetes induction, and administration of
EPS decreased its level slightly, to 1.45 times the normal
value (Fig. 8).
Among the 16 proteins whose expression was de-
creased by STZ-induced diabetes, a2u-globulin, glycopro-
tein 56, Hsc70-ps1, long chain alpha-hydroxy acid oxidase,
neurogenesin 1, and tropomyosin 3 decreased consider-
ably, but increased again after EPS administration, al-
though to different degrees (Fig. 8). The levels of a2u-glo-
bulin, glycoprotein 56, long chain alpha hydroxy acid
oxidase, and neurogenesin 1 were only partially restored
to the levels of normal healthy rats by EPS therapy. On
the other hand, EPS administration restored the levels of
Hsc70-ps1 and tropomyosin 3 to values 1.27-fold and
1.31-fold higher than those of normal healthy rats.
Effect of EPS on the pancreas proteome of diabetic
rats
Two-dimensional electrophoresis was used to inves-
tigate differential protein expression in rat pancreas be-
fore and after diabetes induction and after EPS treatment.
The first studies using two-dimensional electrophoresis
for protein separation in relation to islets, b-cell lines
and T1DM were made in the 1980s, and they described
changes in the protein expression pattern in pancreatic
islets from mice with virus-induced hyperglycemia. In
1987, Nepom et al. (115) used two-dimensional electro-
phoresis and immunoprecipitation to analyze HLA (hu-
man leukocyte antigen) molecules from T1DM patients
and demonstrated that hybrid HLA molecules are asso-
ciated with heterozygosity. Other investigators have used
two-dimensional electrophoresis to describe insulin se-
cretory granule biogenesis, exocytosis and the effect of
glucose on b-cells (116). More recent studies have ana-
lyzed the proteome of pancreatic islets, but have not di-
rectly addressed the pathogenesis of T1DM (117–122). Fur-
thermore, pancreatic islets have been studied by proteome
analysis to investigate the effect of the insulin-sensitizer
drug Rosiglitazone on protein expression (72,73).
The pancreatic proteome resulted in more than 2000
individual spots. Thirty-four proteins from a total of
about 500 matched spots were differentially expressed,
of which twenty-six spots were identified as proteins
whose expression had previously been associated with



















































Fig. 8. Alterations in the levels of the significantly regulated rat kidney proteins, where down- and upregulated proteins after diabe-
tes induction are separately illustrated. For each spot, the relative intensity was averaged and expressed as a mean ± S.E. of the
three separate experiments. *p<0.05 vs. Group N or S, **p<0.001 vs. Group N or S. Group notations are the same as in Fig. 4. Abbre-
viations: D1: a2u-globulin; D2: glycoprotein 56; D3: Hsc70-ps1; D4: long chain alpha hydroxy acid oxidase=FMN-dependent alpha
hydroxy acid-oxidizing enzyme; D5: neurogenesin 1; D6: tropomyosin 3; U1: dihydrolipoyllysine-residue succinyltransferase compo-
nent of 2-oxoglutarate dehydrogenase complex, mitochondrial precursor (dihydrolipoamide succinyltransferase component of 2-oxo-
glutarate dehydrogenase complex) (E2) (E2K); U2: phospholipid scramblase 3; U3: 6-pyruvoyl-tetrahydropterin synthase/dimeri-
zation cofactor of hepatocyte nuclear factor 1 alpha
diabetes (Fig. 9). Of these proteins, ten were upregulated
and sixteen were downregulated (p<0.05) after diabetes
induction, and the altered proteins were restored (p<0.05)
upon EPS treatment. We have found for the first time
that carbonyl reductase (18.6-fold, p<0.001) and MAW-
DBP (31.4-fold, p<0.01) were upregulated upon diabetes
induction, and that the levels of these two proteins were
completely restored by EPS treatment. Moreover, we ob-
tained eight unidentified proteins that had not been re-
ported to be related with diabetes mellitus (data not
shown). These results show that EPS treatment after in-
duction of diabetes can be a useful tool in the search for
potential markers for diagnosis and therapeutic manipu-
lation of diabetes mellitus.
How does EPS act as a hypoglycemic agent?
Although little scientific evidence exists, there are
several hypotheses to explain the possible mechanisms
for hypoglycemic action of fungal EPS in diabetic ani-
mals. Firstly, the viscosity of EPS may delay carbohy-
drate absorption, thereby improving the control of hy-
perglycemia, hyperinsulinemia, severe insulin resistance,
and impaired glucose tolerance of diabetic mice (123,124).
Secondly, EPS can, at least in part, restore the immuno-
modulative imbalance caused by diabetes (e.g. enhanc-
ing IL-6 production from splenic macrophages). Thirdly,
EPS may have a beneficial effect on glucose metabolism
in the liver of diabetic animals by increasing the activi-
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Fig. 9. Alterations in the levels of the significantly regulated rat pancreas proteins, where down- and upregulated proteins after dia-
betes induction are separately illustrated. For each spot, the relative intensity was averaged and expressed as a mean ± S.E. of the
three separate experiments. *p<0.05 vs. Group N or S, **p<0.001 vs. Group N or S. Group notations are the same as in Fig. 4. Abbre-
viations: D1: alpha amylase, pancreatic precursor; D2: alpha amylase precursor; D3: casein kinase 1 alpha; D4: cholesterol esterase
preprotein; D5: laminin receptor 1; D6: lithostathine precursor; D7: peroxiredoxin 4; D8: protein disulfide isomerase A3 precursor;
D9: similar to WAC; D10: sterol esterase; U1: acetyl-CoA dehydrogenase; U2: carbonyl reductase; U3: destrin; U4: dismutase; U5:
glucose regulated protein 58 kDa; U6: homeobox protein Hox-A7; U7: HMG-CoA synthase; U8: MAWD binding protein; U9: myosin
light polypeptide 6; U10: nucleotide diphosphate kinase; U11: seven in absentia 1A; U12: similar to alpha glucosidase II, alpha sub-
unit; U13: similar to elastase 3B; U14: similar to eukaryotic translation initiation factor 5A; U15: triacylglycerol lipase; U16: unknown
(protein for MGC:91679)
ties of hepatic glucokinase, hexokinase, and glucose-6-
-phophate dehydrogenase (125,126). Finally, EPS may
neutralize the ability of STZ to cause b-cell damage. It
may even induce regeneration of islet b-cells, given that
EPS administered 48 h after STZ treatment significantly
restored serum insulin and glucose levels. More detailed
biochemical studies of EPS action such as potential anti-
oxidant activity will be necessary to elucidate the mech-
anism by which EPS alleviates diabetes induced by STZ.
These complicated effects of EPS on diabetes can in-
volve the differential expression of many proteins, as
described in the present study.
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